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Conducting polymer nanoparticles for targeted
cancer therapy†
Cite this: RSC Adv., 2015, 5, 37943

Mona Doshi,ab Marissa Krienke,ac Saeid Khederzadeh,ad Henry Sanchez,ag
Alicja Copik,f Jeremiah Oyerf and Andre J. Gesquiere*abde
First and second generation photosensitizers used in photodynamic therapy (PDT) have shown promising
results in clinical applications, aided by recent improvements in light absorption eﬃciency and quantum
yield of singlet oxygen formation. However, these photosensitizers still have several drawbacks that
prevent PDT from being an eﬃcient therapy, including lack of selectivity to diseased tissue, observation
of dark toxicity, and hydrophobicity of the sensitizer. Conducting polymers are promising candidates as
next generation sensitizers for PDT due to their large extinction coeﬃcients (>107 L mol1 cm1), ability
to undergo intersystem crossing to the triplet state at high rates, and triplet energies that are close to
that of oxygen. Targeting of conducting polymer poly[2-methoxy-5-(2-ethylhexyl-oxy)-pphenylenevinylene] (MEH-PPV) nanoparticles to folate receptors (FR) was achieved by development of
blended nanoparticles containing amphiphilic polymer polystyrene graft ethylene oxide functionalized
with carboxylic acid (PS-PEG-COOH) with chemically active moieties that can be functionalized with
folic acid. The resulting organic nanoparticles are buﬀer stable and exhibit excellent biocompatibility in
the dark. The functionalized nanoparticles (FNPs) were studied in OVCAR3 (ovarian cancer cell line, FR+),
MIA PaCa2 (pancreatic cell line, FR), and A549 (lung cancer cell line, marginally FR+). Complete
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selectivity of the FNPs towards FR+ cell lines was found, and is attributed to the hydrophobicity and

DOI: 10.1039/c5ra05125h

large negative zeta potential of the nanoparticles. Quantiﬁcation of PDT results by MTS assays and ﬂow
cytometry show that PDT treatment was fully selective to the FR overexpressing cell line (OVCAR3). No

www.rsc.org/advances

cell mortality was observed for the other cell lines studied here within experimental error.

Introduction
In the last two decades a steady decrease in cancer patient
mortality has been achieved due to intensive research and
improvements in treatments.1 However, for high mortality
cancers such as pancreatic, liver, lung etc. no signicant progress has been made.2 Therefore, a multitude of treatment
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schemes are still being investigated to address existing needs in
cancer therapeutics. Photodynamic therapy (PDT) is receiving
increasing attention among researchers due to its ease of
application and promising clinical results.3,4
In PDT a photosensitizer is administered to tissue and irradiated with visible light matching to the absorption spectrum of
the photosensitizer.5,6 This brings the photosensitizer into its
singlet excited state, which can then relax to the ground state
through diﬀerent pathways. Decay of the excited state by uorescence makes it possible to use some sensitizers as a tool to
locate diseased tissue, but only if the photosensitizer is targeted
to that tissue. A fraction of the singlet excited state of the
photosensitizer will intersystem cross to its long lived triplet
excited state. The triplet state leads to the formation of Reactive
Oxygen Species (ROS), highly reactive forms of oxygen, which
are harmful to cells and can result in cell mortality.7–9 The
mechanism by which the triplet state of the photosensitizer
leads to formation of ROS involves two types of photooxidative
pathways. In type I photooxidation charge transfer from the
triplet state of the photosensitizer to molecular oxygen yields
the reactive superoxide radical ion. Alternatively, this process
can proceed with biomolecules and solvent molecules in the
cells as the acceptors to form radicals. In type II photooxidation
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the triplet state of the photosensitizer transfers energy to the
triplet ground state of oxygen to form singlet oxygen.5,7,10,11 The
resulting elevated levels of ROS induce oxidative stress and cell
death.5,7,10,12,13
When a non-targeted photosensitizer is administered into
the body, the patient has to be kept away from sunlight in order
to avoid toxic side eﬀects. Photosensitizers such as verteporn,
5-aminolevulinic acid, and photofrin cause skin diseases that
manifest themselves by pigmentation, and phototoxic reactions
which cause itching and burning sensation, swelling and
erythema.14,15 To address such side eﬀects, the photosensitizer
must be targeted towards the malignant tissue only. Nanoparticle technology has shown promise to improve the eﬃcacy
and selectiveness of sensitizer delivery towards malignant
tissue, causing less side eﬀects. During the last decade, monoclonal antibodies (MAbs) have been used to target cancers for
diagnosis and treatment.16 In photoimmunotherapy (PIT),
MAbs were conjugated with photosensitizers such as haematoporphyrin derivative (HpD), chlorin e6 and phthalocyanines
to achieve selective delivery of the photosensitizer in tumors.16
However, the current issue with PIT is optimal control over the
conjugate preparation without changing the biological properties of the monoclonal antibodies.16 Besides targeting cancers
through specic antibody/antigen interactions, cancer cells can
also be targeted by means of the well-documented overexpression of receptors such as folate receptors (FR),17,18
epidermal growth factor receptors (EGFR),19 Her-2 receptors20,21
and others depending on the type of cancer. Ligands specic
towards these receptors such as folic acid (FA), antibodies
Erbitux or Cetuximab, and aﬃbody, respectively, can be used
for enhanced selectivity of delivery. Research has been reported
on targeting ovarian cancer with diﬀerent ligands to make PDT
more specic. Recently PDT using Fe3O4/Au NPs decorated with
5,10,15,20-tetrakis(4-hydroxyphenyl)-21H,23H-porphine (tHPP)
as a photosensitizer and aﬃbody for Her-2 specicity to target
SK-OV-3 ovarian cancer cells was studied.22 These NPs were
evaluated in xenograed tumor and were found to be very
eﬀective in showing specicity and inhibition of tumor growth.
EGFR targeted PDT using liposomes functionalized with
Cetuximab as the targeting antibody and benzoporphyrine
derivative (BPD) as photosensitizer yielded very promising
results when applied to ovarian cancer cells.23 Research on the
use of folic acid as a ligand for selective delivery of photosensitizer in diﬀerent types of cancer tissues is also welldocumented and is still in progress. Polymeric micelles conjugated with folic acid to deliver meta-tetra (hydroxyphenyl)
chlorin (mTHPC) in KB cells in vitro and corresponding xenogras were studied by Syu et al.24 CdTe quantum dots acting as a
photosensitizer and conjugated with folic acid showed specicity to folate receptor (FR) overexpressing KB cells.25 Similarly,
zinc tetraaminophthalocyanine (ZnaPc) conjugated with folic
acid showed selective delivery of the photosensitizer to FR
positive (FR+) KB cells.26 Graphene oxide nanoparticles loaded
with photosensitizer chlorin e6 (Ce6) and conjugated with folic
acid recently showed promise when studied in vitro with
MGC803 cells.27

37944 | RSC Adv., 2015, 5, 37943–37956

Paper

Photosensitizers that are currently applied in PDT have
moderate extinction coeﬃcients and have high singlet oxygen
quantum yield, which has provided promising result for PDT
treatment in clinical settings.28,29 Though a lot of work has been
completed to improve the properties of photosensitizers to
make PDT an eﬀective treatment for cancer with only minor to
no side eﬀects, there still remain a few problems that need to be
addressed. These include (1) lack of specicity, which leads to
side eﬀects such as damage to healthy tissue and prolonged
photosensitivity of the patient, (2) hydrophobicity of sensitizer
molecules that leads to aggregation and thus reduced
bioavailability and eﬃcacy of the photosensitizer, and (3) dark
toxicity of the photosensitizers, which could limit applicability
of the photosensitizer, especially if non-targeted sensitizers.
Photosensitizer doped conjugated polymer nanoparticles
have recently received attention as next generation photosensitizers in PDT. Grimland et al. have recently studied conducting polymer nanoparticles acting as nanocarriers encapsulating
the photosensitizer tetraphenylporphyrine (TPP).30 The investigators showed formation of singlet oxygen by UV-vis spectroscopy aer photoactivating the nanoparticles by one and two
photon excitation. As a proof-of-concept DNA damage was
shown in presence of these nanoparticles. Shen et al. also
proved the generation of singlet oxygen by tetraphenylporphyrine (TPP) doped in conjugated polymer nanoparticles by
photoluminescence of singlet oxygen by uorescence spectroscopy.31 Similarly, Zhang et al. used meta-tetra-(hydroxyphenyl)chlorin (m-THPC) as the photosensitizer in conjugated polymer nanoparticles to form ROS.32
In this article, blended poly[2-methoxy-5-(2-ethylhexyl-oxy)-pphenylenevinylene] (MEH-PPV)/polystyrene gra ethylene oxide
functionalized with carboxylic acid (PS-PEG-COOH) nanoparticles conjugated with folic acid (FNPs) were studied in vitro
for use in PDT as next generation photosensitizers with targeted
delivery. The nanoparticles were fabricated by self-aggregation
of the polymer; the only chemistry that was applied was to
conjugate folic acid to the nanoparticles. The FNPs are not
cytotoxic in dark, and are highly eﬀective at producing ROS
under illumination due to the large extinction coeﬃcient of
MEH-PPV (>107 L mol1 cm1). The combination of the
hydrophobicity of MEH-PPV, large negative zeta potential of the
nanoparticles, and receptor mediated uptake resulted in
complete selectivity of FNP uptake by cancer cell lines that
overexpress folate receptors (FR). Among the cancer cell lines
studied MIA PaCa2 (pancreatic cancer cell line, no FR overexpression) does not show detectable uptake of FNPs, A549
(lung cancer cell line, minor FR overexpression) shows minor
FNP uptake, and OVCAR3 (ovarian cancer cell line, major FR
overexpression) shows abundant FNP uptake. PDT results
quantied by MTS assay and conrmed by ow cytometry scale
with the observed FNP uptake as expected. These results indicate the promising nature of this photosensitizer system due to
its lack of dark toxicity, inclusion of PEG for enhanced circulation times, high rate of ROS generation, high cell mortality for
the cancer cell line that abundantly overexpresses the targeted
receptor (OVCAR3), while no cell mortality is observed for nontargeted (TE 71 normal control and MIA PaCa-2) or marginally
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receptor overexpressing cell lines (A549), and bright uorescence that together with the high degree of selectivity can be
used to localize the targeted tissue.

Experimental section
Published on 15 April 2015. Downloaded by University of Central Florida on 12/6/2018 7:29:46 PM.

Materials
Poly[2-methoxy-5-(2-ethylhexyloxy)-1,4-phenylenevinylene] (MEHPPV) with molecular weight 150 000–250 000 g mol1 (average
Mn, PDI 2.2) was purchased from Sigma-Aldrich. For molarity
calculations Mn of 200 000 g mol1 (Mw ¼ 4.4  105 g mol1)
was used. The polymer was puried to remove low molecular
weight polymer chains. Comb-like polymer Polystyrene Gra
Ethylene Oxide functionalized with carboxylic acid (PS-PEGCOOH) with molecular weight of 36 500 g mol1 (average Mn,
PDI 1.3, Mw ¼ 47 450 g mol1) was purchased from Polymer
Source Inc and used as is. THF (tetrahydrofuran, Drisolv) was
purchased from EMD. N-Hydroxysuccinimide (NHS), N-(3-dimethylaminopropyl)-N0 -ethylcarbodiimide hydrochloride (EDC) and
folic acid were purchased from Sigma-Aldrich.

Purication of MEH-PPV
To purify MEH-PPV 6 ml of HPLC grade acetone was added to 3
mg MEH-PPV in a vial. The vial was heated gently at a low
temperature on a hot plate. The supernatant was observed to
turn yellow and was removed using a glass pipette without
removing the MEH-PPV at the bottom of the vial. A small
amount of chloroform (approximately 3 ml) was added to this
vial to dissolve MEH-PPV. To this orange solution acetone was
added in a 1 : 5 ratio of chloroform to acetone. This suspension
was transferred to a centrifuge tube and centrifuged for 10
minutes at 4000 rpm. The high molecular weight MEH-PPV
settled at the bottom while the low molecular weight MEHPPV remained in the supernatant. The supernatant was
removed and the procedure was repeated until the supernatant
showed a light pink color (around four repetitions). The puried
MEH-PPV was dried overnight before use.

Fabrication of MPNPs
1 mg puried MEH-PPV was dissolved in 3 ml THF to obtain a
0.33 mg ml1 stock solution of MEH-PPV and 1 mg PS-PEGCOOH was dissolved in 50 ml THF to obtain a 0.02 mg ml1
solution of PS-PEG-COOH. An approximately 2 : 1 molar ratio
solution of MEH-PPV and PS-PEG-COOH was prepared by
adding 1 ml of MEH-PPV stock solution to 1 ml PS-PEG-COOH
stock solution. This mixture was then diluted further with
approximately 3 ml THF to achieve a 106 M concentration of
MEH-PPV and PS-PEG-COOH. 1 ml of this diluted solution
was quickly injected into 4 ml of DI water under vigorous
stirring. Stirring was stopped immediately aer injection of
the solution into water. The resulting suspension of MPNPs
(MEH-PPV–PS-PEG-COOH blended nanoparticles) in water
was used for preparation of folic acid functionalized nanoparticles (FNPs).

This journal is © The Royal Society of Chemistry 2015
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Functionalization of MPNPs
To chemically link folic acid to the MPNPs, the carboxylic acid
groups of PS-PEG-COOH present in these MPNPs were rst
activated with NHS and EDC. NHS was added in excess to the
MPNP suspension. Aer 15 minutes of stirring excess EDC was
added to this solution. The solution of MPNPs, NHS and EDC
was stirred again for 15 minutes. As folic acid is not soluble in
water, it was dissolved in 1 M sodium hydroxide rst and then
was added to the solution of MPNPs reacted with NHS/EDC in a
1 : 1 molar ratio of PS-PEG-COOH : folic acid. This solution was
stirred for 2 hours at room temperature. The solution obtained
is unltered functionalized nanoparticles (unltered FNPs).
Centrifugal ltration of FNPs
15 ml of FNPs were ltered by centrifugal ltration to remove
the unreacted folic acid, NHS and EDC from the solution.
Amicon Ultra-15 centrifugal lter devices with molecular weight
cutoﬀ 10 000 kDa was used for ltration. The solution was spun
at 4000g in a swinging bucket rotor for 60 minutes. To remove
the unreacted NHS, EDC and folic acid from the FNPs solution,
6 to 7 ltrations were needed. Aer each ltration cycle
approximately 3 ml of ltrate were removed and the volume of
the FNPs solution was adjusted back to 15 ml by adding DI
water, eﬀectively replacing the unreacted folic acid, NHS and
EDC from the solution with DI water. Progress was monitored
by UV-vis and uorescence spectroscopy completed for each
ltrate (Fig. S3†).
UV-visible spectroscopy
Absorption spectroscopy on the NPs suspension in water was
done in a 1 cm path length quartz cuvette with Agilent 8453
spectrophotometer using UV-visible chemstation soware.
Fluorescence spectroscopy
Fluorescence spectroscopy on the NPs suspension in water was
performed in a 1 cm path length quartz cuvette with Nanolog™
HoribaJobin Yvon uorimeter.
Cell culture
TE 71 (mouse thymic epithelial cell line), MIA PaCa-2 (human
pancreatic cancer cell line), A549 (human lung cancer cell line)
and OVCAR3 (human ovarian tumor cell line) were grown in
DMEM media supplemented with 10% FBS in humidied
atmosphere of 95% air/5% CO2 at 37  C.
Incubation with NPs for uorescence imaging
TE 71, MIA PaCa-2, A549 and OVCAR3 cell lines were grown in
35 mm Petri dishes for 24 hours. Then the media was removed
and aer washing with PBS the cells were incubated with 2 
104 mg ml1 NPs in DMEM media supplemented with 10%
FBS. Aer 24 hours the NPs solution was removed and cells were
washed with PBS. Then the cells were xed with 4% paraformaldehyde and stained with DAPI and suspended in PBS to
image.
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Imaging for uptake of NPs
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The xed cells were imaged by epiluminescence microscope
(Olympus IX 51) by using 60 objective, mercury lamp for
uorescence and FITC lters to detect the uorescence from
NPs and DAPI lters to detect uorescence from nucleus
stained with DAPI. The images were acquired by Andor Zyla
sCMOS (DG-152V-C1E-FI) camera The NP images and DAPI
images were overlaid using ImageJ (NIH) soware.
Flow cytometry for uptake quantication
1  106 cells per ml concentration solutions of TE 71, MIA PaCa2, A549 and OVCAR3 cell lines were incubated with 2  104 mg
ml1 FNPs for 24 hours. Then the cells were harvested, washed
and xed with 4% paraformaldehyde and ow cytometry was
performed on these samples by BD Canto II ow cytometer. The
data was analyzed by using FlowJo soware.
Intrinsic cytotoxicity of FNPs
The cells were grown in 96 well plates and were incubated with
the diﬀerent doses of FNPs (0.4  104 mg ml1, 2  104 mg
ml1 and 3.6  104 mg ml1) along with one control dose (0
mg ml1) cells were incubated with CPNPs for up to 24 hours.
Cell viability was determined 0, 24, 48, 72 and 96 hours aer
addition of CPNPs by MTS assay. For the 0 and 24 hour time
point, MTS was added immediately aer adding FNPs and 24
hours aer addition of CPNPs, respectively. For the 48, 72 and
96 hours readings, the FNPs solution was removed aer 24
hours and replaced with regular media (DMEM media supplemented with 10% FBS). MTS was then added at the corresponding time points. MTS was allowed to incubate for 4 hours
to allow formazan to form. Then the readings were taken at 490
nm on Biotek ELx800 absorbance microplate reader.

Paper

from DAPI stained to nucleus. FNP uorescence was collected
by using excitation lter 488/10 and emission lter 600LP. The
images were overlaid using ImageJ (NIH) soware.
Viability aer PDT treatment
Three light doses (60 J cm2, 120 J cm2 and 180 J cm2) and
three FNPs doses (0.4  104 mg ml1, 2  104 mg ml1 and
3.6  104 mg ml1) along with one control dose (0 mg ml1)
were used for PDT. For each light dose two post-PDT incubation
periods (0 hours and 4 hours) were given. Thus cell lines were
grown in six 96-well plates (3 light doses  2 post-PDT incubation periods). The cell lines were grown for 24 hours. Then
the cells were incubated with diﬀerent doses of FNPs. Aer 24
hours the media was replaced with HBSS and the 96 well plates
with the cells were exposed to visible light by using a solar
simulator (Newport 67005 Oriel Instruments) and a UV lter
(FSQ-GG400) to block the UV light. Then MTS was added to the
96 well plates immediately aer PDT (0 hours) and 4 hours postPDT incubation. MTS was allowed to incubate for 4 hours to
allow formazan to form. Then the readings were taken at 490
nm on Biotek ELx800 absorbance microplate reader. The
experiment was performed 3 times (n ¼ 3).
Flow cytometry for apoptosis and necrosis
1  106 cells per ml concentration solutions of TE 71, MIA PaCa2, A549 and OVCAR3 cell lines were incubated with 2  104 mg
ml1 FNPs for 24 hours. Then the cells were irradiated with 180
J cm2 light dose and incubated for another 4 hours. Then the
cells were harvested and stained with annexin V-FITC and PI
(propidium iodide). The samples were kept on ice. Flow
cytometry was performed on these samples by BD Canto II ow
cytometer. The data was analysed by using FlowJo soware.

Detection of ROS

Results and discussion

The TE 71, MIA PaCa-2, A549 and OVCAR3 cells were incubated
with 2  104 mg ml1 of FNPs. Aer 24 hours the media was
replaced with HBSS (Hank's Balanced Salt Solution) and 180 J
cm2 light dose was given by using Newport 67005 Oriel
Instruments and a UV lter (FSQ-GG400) to block the UV light.
The CellROX green reagent purchased from Invitrogen was
added to the media aer 2 hours of post-PDT incubation. Aer
30 minutes the reagent was washed and the cells were xed with
4% paraformaldehyde and stained with DAPI. The cells were
kept in PBS for imaging. 3 negative controls (1) no FNPs and no
light dose, (2) only light dose of 180 J cm2, and (3) only FNPs
dose of 2  104 mg ml1, and one positive control with 100 mM
H2O2 were also performed.

1. Fabrication, functionalization and characterization of
NPs

Imaging for ROS detection
The xed cells were imaged by epiluminescence microscope
(Olympus IX 51) by using 60 objective and mercury lamp for
uorescence. The images were acquired by Andor Zyla sCMOS
(DG-152V-C1E-FI) camera. Excitation lter 491/10 and emission
lter 525/50 were used to detect the uorescence from CellRox
green reagent. DAPI lters were used to detect uorescence
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The nanoparticles (NPs) to be functionalized were fabricated by
the reprecipitation method, following a modied procedure
from the one published by Wu et al.33 In short, a solution of 2 : 1
molar ratio of uorescent hydrophobic polymer MEH-PPV and
non-uorescent comb-like amphiphilic polymer PS-PEG-COOH
in THF was quickly injected into DI water under vigorous stirring. Due to their hydrophobicity, the MEH-PPV polymer chains
and the polystyrene backbone of PS-PEG-COOH polymer
aggregate to form MPNP suspension in water. The hydrophilic
PEG and COOH parts of the non-uorescent polymer extend
towards water making the carboxylic acid groups available on
the surface of the MPNPs for further modications. The
carboxylic acid groups were then allowed for attachment of
ligands to the MPNPs. Scheme 1 shows the complete process of
MPNP fabrication and functionalization by conjugation of folic
acid to the COOH groups.
Aer MPNP fabrication NHS and EDC was added to the
MPNPs suspension (Scheme 1 step 2 and 3) in order to activate
the hydroxyl groups of COOH on the MPNPs surface by forming

This journal is © The Royal Society of Chemistry 2015
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Scheme 1 Functionalization of MPNPs with folic acid by EDC reaction. (1) Formation of MPNPs from mixed solution of MEH-PPV and PS-PEGCOOH in THF, (2) and (3) addition of NHS and EDC respectively to activate the carboxyl OH groups, forming the O-acylisourea group on MPNPs,
(4) conjugation of folic acid to MPNPs through the formation of an amide bond.

the O-acylisourea product, which is a better leaving group. Upon
addition of 1 : 1 molar ratio of folic acid to PS-PEG-COOH in the
O-acylisourea product, folic acid conjugates to the MPNPs by
formation of an amide bond between the amine of folic acid
and the carbonyl group of MPNPs while replacing the isourea
group (Scheme 1 step 4). Unreacted folic acid was removed by
centrifugal ltration. The ltered solution is a suspension of the
functionalized NPs (FNPs) in water.
Formation of an amide bond between the carbonyl of MPNPs
and amine of folic acid was conrmed by FTIR. Fig. 1A shows
the FTIR spectra of MPNPs, FNPs and MEH-PPV NPs. Fig. 1B
has the same spectra enlarged from 1000 to 2000 cm1. There

This journal is © The Royal Society of Chemistry 2015

are no major diﬀerences between the spectra of MPNPs and
MEH-PPV NPs suggesting that there is no chemical bond
formation when PS-PEG-COOH and MEH-PPV polymers were
mixed with each other to fabricate MPNPs. Three particular
amide bands in the FTIR spectrum of FNPs (blue line), (1) amide
I – C]O stretch at 1620 cm1, (2) amide II – NH bend at 1580
cm1, and (3) amide III – 1312 cm1,conrm that the expected
amide bond was formed. There is one primary amine (pterine
ring) and one secondary amine (p-aminobenzoate moiety) in
folic acid (Scheme 1) which can form an amide bond with the
carbonyl on MPNPs.34,35 Chen et al. have recently shown that
even though the pterine moiety in folic acid is essential for the

RSC Adv., 2015, 5, 37943–37956 | 37947
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(A) FTIR spectra of FNPs (blue line) compared with MEH-PPV NPs (black line) and MPNPs (red line). The three particular amide bands at
1620 cm1 – (amide I) for C]O stretch, 1580 cm1 (amide II) for NH bend and 1312 cm1 (amide III) in FNPs spectrum conﬁrm the formation of
amide bond between amine of folic acid and carbonyl on MPNPs.
Fig. 1

binding aﬃnity to folate receptors, extensive interactions
between the glutamate group in folic acid and side chains of the
proteins lining the groove of folate receptors could be observed,
specically through six hydrogen bonds and some backbone
interactions.36 Thus even if the primary amine in the pterine
ring is compromised during the conjugation of folic acid to
MPNPs, the uptake eﬃciency should not be signicantly
aﬀected. Also, the conjugation might have occurred through the
secondary amine of p-aminobenzoate moiety of folic acid. The
uptake measurements in OVCAR3 cell line (vide infra) show that
the uptake eﬃciency was indeed not compromised.
The zeta potential measurements revealed that the MPNPs
have a negative zeta potential of 50.8  6.21 mV on them. The
high negative charge on MPNPs might be due to the COOH
groups protruding out on the surface of MPNPs. This also
conrms the assumption that the hydrophilic parts of PS-PEGCOOH extends out on the surface of MPNPs. The FNPs also have
a zeta potential of 48.9  8.36 mV due to the few conjugated
folic acid molecules and the remaining unreacted COOH
groups on the surface of FNPs.
The optical properties of the MPNPs and FNPs were
measured by UV-vis and uorescence spectroscopy (Fig. 2A and
B). The UV-vis spectra (Fig. 2A) of the MPNPs (black line) and
FNPs before centrifugal ltration (red line) have lmax 497 nm
while the lmax of FNPs aer centrifugal ltration (blue line) is
blue shied by 5 nm and has lmax at 492 nm. The blue shi in
the lmax might be attributed to compacting of the FNPs and
collapse of polymer chains within the FNPs when residual THF
is extracted from the FNPs during the centrifugal ltration. The
collapse of the polymer chains inside the FNPs leads to severe
kinking and bending of conjugated backbone of polymers
which results in reduced conjugation length leading to the blue
shi in absorption spectra.37–40
The uorescence spectra (Fig. 2B) of MEH-PPV have lmax at
589 nm, even though the uorescent intensity of the FNPs aer
ltration is drastically reduced to 40%. This eﬀect again can be

37948 | RSC Adv., 2015, 5, 37943–37956

attributed to the removal of THF during centrifugal ltration.
When THF is removed the FNPs may become compacted, which
can result in lowered quantum eﬃciency of uorescence due to
self-quenching.41
The presence of folic acid in FNPs suspension was conrmed
by acquiring emission of folic acid by exciting the FNPs at 300
nm (Fig. 2C). The uorescence spectrum of folic acid in FNPs
before ltration (red line) has lmax at 402 nm. Aer ltration the
uorescence intensity of folic acid in FNPs (blue line) decreases
as the unreacted folic acid is removed from the solution,
although the lmax remains unaltered.
It has previously been reported that MEH-PPV NPs fabricated
by the reprecipitation method have a diameter of about 35 nm
in diameter.39 When MPNPs were fabricated from a mixture of
2 : 1 molar ratio of PS-PEG-COOH and MEH-PPV by the reprecipitation method, the size was measured to be 45.12  4.60 nm
by DLS (Table 1). Aer folic acid conjugation the size of FNPs
before ltration decreased slightly to 39.81  5.12 nm as
compared to MPNPs. Aer ltration the size of FNPs increased
to 68.80  7.30 nm, which is attributed to aggregation of a few
FNPs (see Fig. S1 for AFM images and S2 for DLS data in the
ESI†).
2. Uptake of NPs
As the zeta potential on the surfaces of FNPs is 48.9  8.36 mV,
it was expected that due to such a high negative charge there
would be no or limited non-specic uptake of FNPs in any of the
cell lines.42–45 Due to the presence of folic acid on FNPs, it was
speculated that regardless of the high negative charge on the
surfaces of FNPs, a receptor mediated uptake of FNPs would
occur in cell lines which overexpress folate receptors (FRs) on
their cell membranes. Fig. 3 shows the qualitative uptake of
FNPs in OVCAR3, A549, MIA PaCa-2, and TE-71 cell lines by
epiluminescence imaging. As it is well known that over 90% of
ovarian cancer cells overexpress FRs,17,46–49 and the expression of
FRs on ovarian carcinoma is very homogenous,50 the OVACR3
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Fig. 2 (A) UV-vis spectra of NPs suspended in water. The absorption maxima for MPNPs and FNPs before ﬁltration are 497 nm. After ﬁltration the
absorption maximum shifts to 492 nm. NP ﬂuorescence spectra were collected for excitation at (B) MEH-PPV absorption and (C) folic acid
absorption. The lmax of emission spectra in (B) for the three diﬀerent NPs is 589 nm, although the intensity of ﬂuorescence is reduced to
approximately 40% after ﬁltration. In (C) the ﬂuorescence of folic acid has lmax at 402 nm. After ﬁltration the observed intensity of folic acid
ﬂuorescence is reduced due to removal of unreacted folic acid from FNP solution (also see Fig. S3†). Table 1 shows the size of NPs determined by
DLS and the zeta potential on their surfaces. For the unﬁltered FNPs zeta potential data could not be obtained due to the free folic acid and
excess NHS and EDC present in solution.

Fig. 3 Uptake of FNPs in OVCAR3, A549, MIA PaCa-2 and TE 71 cell lines. The ﬂuorescence images represent FNPs ﬂuorescence (green) and
DAPI ﬂuorescence (blue). The corresponding phase contrast images are also shown. The left column shows the control images, the middle
column shows images for cells treated with MPNPs and the right column shows images for cells treated with FNPs.

This journal is © The Royal Society of Chemistry 2015
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cell line was selected as the FR positive (FR+) cell line to observe
the specic or receptor mediated uptake of FNPs. The expression of FRs in A549 is marginal at best, if not absent,49,51–59 while
in the MIA PaCa-2 cell line there are receptors other than FRs
(FR), like thrombin receptors60 or EGFR.61 Thus these two
cancer cell lines were chosen as negative controls. The TE 71 cell
line was chosen as a control normal cell line which has
marginal to no FRs. It was observed that when all four cell lines
were incubated with 2  104 mg ml1 dose of FNPs, the uptake
of FNPs was highest in OVCAR3 due to high amount of FRs
expressed in this cell line, while in A549 the uptake of FNPs was
limited as it has few to no FRs. MIA PaCa-2 and TE 71 have no
detectable uorescence suggesting no uptake of FNPs in these
cell lines. To rule out the possibility of non-specic uptake in
OVCAR3 or in A549 all the cell lines were incubated with an
equal dose of MPNPs, which are not conjugated with folic acid
(Fig. 3). It was observed that there was no detectable uorescence from MPNPs in any of the four cell lines suggesting that
there was no non-specic uptake of MPNPs. This observation
infers that for receptor mediated uptake of NPs, the presence of
FRs on cell membranes and the presence of folic acid on the
NPs surface was necessary.
To determine the selectivity of FNP uptake, ow cytometry
was performed on the cell lines aer incubating them with a 2
 104 mg ml1 dose of FNPs. Fig. 4 shows the ow cytometry
results. TE 71, MIA PaCa-2 and A549 data show that 0% cell
population has uptaken FNPs, while for the OVCAR3 cell line
85% of the cell population has uptaken FNPs. Although epiluminescence imaging shows small amounts of FNPs in A549
cells, ow cytometry was unable to detect this uorescence. In
addition, PDT did not induce cell mortality in this case (vide
infra). The selectivity of the FNPs towards OVCAR3, which is the
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folate overexpressing cell line, is easily explained by the conjugation of the FNPs with folic acid, while the limited uptake by
A549 is attributed to the few FRs available on the cell surface. In
addition, the lack of uptake by the other cell lines can be
attributed to the hydrophobicity and the high negative zeta
potential of the FNPs, which makes non-receptor mediated
uptake unlikely.
3. Intrinsic cytotoxicity of FNPs
The cytotoxicity of the FNPs in dark (intrinsic cytotoxicity) was
studied by quantifying the proliferation of the cell lines in
presence of FNPs by MTS cell viability assay. Data are shown in
Fig. 5 for TE 71, MIA PaCa-2, A549 and OVCAR3 cell lines. For
each cell line the % cell viability at each FNPs dose is normalized to the control dose. Cell viability was observed to be about
100% at each dose of FNPs up to 96 hours. No cell mortality is
observed for the TE 71 and MIA PaCa-2 cell lines, which at rst
glance appears trivial due to the lack of FNP uptake. However,
the presence of the FNPs in the cell culture media also did not
result in cell mortality. For A549 limited FNP uptake was
observed, while for OVCAR3 abundant FNP uptake occurred
(Fig. 3). Again, in neither case cell mortality is observed. The
FNPs clearly do not aﬀect the normal functioning of cells, and
cells in the presence of FNPs proliferate normally (Fig. S4†).
4. Generation of oxidative stress in cells aer PDT
It is well known that when conducting polymers absorb light, it
can intersystem cross and form triplet excited states. In case of
MEH-PPV the probability of intersystem crossing and forming
triplet excited states is 1.25%.62 These triplet states can dissipate
to the ground state by energy transfer to triplet ground state of

Uptake of FNPs was quantiﬁed by ﬂow cytometry for the (A) TE 71, (B) MIA PaCa-2, (C) A549, and (D) OVCAR3 cell lines. Red line –
normalized percent population of control cells, Green line – normalized percent population of cells incubated with FNPs. (E) Bar graph indicating
the percentage of the cell population that has uptaken FNPs compared to the control (no FNPs). (F) Bar graph indicating the average ﬂuorescence
intensity of FNPs detected for the diﬀerent cell lines.

Fig. 4
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Fig. 5 Intrinsic cytotoxicity of FNPs quantiﬁed by MTS viability assay for (A) TE 71, (B) MIA PaCa-2, (C) A549, and (D) OVCAR3 cell lines incubated
with diﬀerent doses of FNPs and kept in dark. MTS assays were run up to 96 hours after incubation with FNPs.

molecular oxygen to form the highly reactive singlet oxygen
(type I photooxidation).5,7,10,11 In other instances, charge transfer
can occur to molecular oxygen to form superoxide or to other
substrates such as solvent molecules and biomolecules (lipids,
DNA, nucleic acids etc.) to form radicals (type II photooxidation).5,7,10,11 The reactive superoxide radicals then form
hydrogen peroxide by grabbing an electron which in presence of
Fe(II) can form hydroxyl radicals.63–66 The hydroxyl radicals lead

This journal is © The Royal Society of Chemistry 2015

to lipid peroxidation and cause damage to cell organelles.64
Thus it was hypothesized that MEH-PPV, upon photoexcitation
would eﬀectively photosensitize the formation of singlet oxygen
or superoxide radicals, and that FNPs would not require a
photosensitizing dopant.
The generation of ROS in cells treated with FNPs and irradiated with light, i.e. PDT experiment, was detected by CellRox
Green reagent (CGR). CGR has weak to no uorescence in its

RSC Adv., 2015, 5, 37943–37956 | 37951

View Article Online

Published on 15 April 2015. Downloaded by University of Central Florida on 12/6/2018 7:29:46 PM.

RSC Advances

reduced form. When CGR is oxidized by ROS in the cells, it
displays bright green uorescence. Fig. 6D shows epiluminescence images of OVCAR3, A549, MIA PaCa-2 and TE 71
cell lines administered with 2  104 mg ml1 FNPs and photoirradiated with 180 J cm2 of light. Aer PDT the cells were
incubated for 2 hours before staining with CGR. The CGR
uoresces bright green only in the OVCAR3 cell line as only
OVCAR3 has uptaken FNPs and so ROS are generated only in
this cell line turning the CGR color bright green. Even though
the A549 cell line has shown small amounts of FNP uptake
(Fig. 3), that amount is not suﬃcient to produce ROS detectable
by CGR. MIA PaCa-2 and TE 71 cell lines show no emission from
CGR as there was no uptake of FNPs, hence no ROS formation.
The fact that ROS formation in the cells is due to PDT and
not intrinsic cytotoxicity of FNPs such as previously observed
for, for instance, quantum dots, which lead to elevated ROS
even in absence of light,67,68 was conrmed by performing three
negative controls stained with CGR shown in Fig. 6A–C (A) in
absence of PDT (no FNPs, no light), (B) in absence of FNPs with
180 J cm2 light dose, and (C) in absence of light with 2  104
mg ml1 FNPs dose). As no emission from CGR was observed in
Fig. 6B, it can be concluded that there is no ROS formation in
absence of FNPs and that the light dosage alone did not form
ROS. Thus, there is no phototoxicity up to the 180 J cm2 light
dose. The phase contrast images show that the light has no
adverse eﬀect on the morphology of the cells. Fig. 6C shows no
CGR emission in any of the four cell lines when the cells are
administered with FNPs but are not irradiated with light. This
conrms that ROS are not formed when the FNPs are not
photoactivated. This is also a conrmation of the negative
results of the intrinsic cytotoxicity by MTS assay when cells are
kept in dark (Fig. 5). These negative controls show that FNPs
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uptaken by the cells and exposed to light are the source of ROS
formation, hence the oxidative stress in the cells. Fig. 6E is the
positive control for formation of ROS in which all the cell lines
are treated with 100 mM H2O2.
5. Quantitative measurements on cell viability aer PDT
The quantitative eﬀect of PDT on the studied cell lines was
measured by MTS cell viability assays. Fig. 7 shows the % cell
viability aer PDT. For each cell line the viabilities at the three
diﬀerent FNPs doses (0.4  104 mg ml1, 2  104 mg ml1
and 3.6  104 mg ml1) is compared with the viability at the
control FNPs dose (0 mg ml1). MTS assay was performed
immediately aer PDT (Fig. S5†) and 4 hours post-PDT to
evaluate further progression aer PDT (Fig. 7). It was shown
previously that with the use of composite MEH-PPV/PCBM NPs
for PDT, 4 hours is a suﬃcient time to cause nearly 100% cell
mortality.69 The measurements revealed that the viability of TE
71, MIA PaCa-2 and A549 cell lines is almost 100%. In OVCAR3
cell line, the viability decreases with increase in FNPs dose. It is
a well-accepted fact that 90% of ovarian cancer cells overexpress
FRs,17,46–49 and the expression of FRs on ovarian carcinoma is
very homogenous.50 Therefore, the OVCAR3 cell line is considered as the FR+ cancer cell line. Thus, there is preferential
uptake of the folic acid conjugated nanoparticles by ovarian
cancer cells through receptor mediated uptake.70,71 In A549 the
expression of FRs is marginal although not completely
absent.17,18,72 In MIA PaCa-2 there is no FR overexpression.60,61
and so this is considered as the FR cancer cell line. The TE 71
cell line has little to no FR expression and is the normal control
cell line. Due to high overexpression of FR in OVCAR3 the
uptake of FNPs is abundant through receptor mediated endocytosis. As the FNPs dose increases the amount of FNPs uptaken

Fig. 6 Detection of ROS generated after PDT in TE 71, MIA PaCa-2, A549 and OVCAR3 cell lines. (A) negative control (no FNPs, no light), (B)
negative control with 180 J cm2 (no FNPs) indicates no photocytotoxicity is observed, (C) negative control with 2  104 mg ml1 FNPs (no light)
indicates no intrinsic cytotoxicity, (D) 2 hours post-PDT, (E) positive control with 100 mM H2O2. The green color in (C) is ﬂuorescence of FNPs. The
green color in E is CellRox green dye oxidized due to the presence of ROS.
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Fig. 7 MTS cell viability assay to quantify results from PDT for TE 71, MIA PaCa-2, A549 and OVCAR3 cell lines incubated with diﬀerent doses of

FNPs and irradiated with 3 doses of light. The post-PDT incubation time is 4 hours (see Fig. S5† for 0 hours post-PDT incubation time).

by the OVCAR3 cells increases. At the same time the population
of cells that uptake FNPs also increases. This increase in
amount of FNPs in many cells leads to formation of more ROS
in the large number of cells, which reects in low percent cell
viability. In MIA PaCa-2 due to absence of FR expression, no
FNPs uptake occurred and so the viability is almost 100%. For
A549 there is small uptake of FNPs due to less FR expression
(Fig. 3). The amount of FNPs is not suﬃcient to result in
oxidative stress in the A549 cell line. Thus the viability is
approximately 100%. The TE 71 which also has little to no
overexpression of FRs on the plasma membrane, there is no
uptake of FNPs and cell viability is 100%. Also, as the light dose
increases (60 J cm2, 120 J cm2 and 180 J cm2) the cell
viability in OVCAR3 cell line decreases implying a larger amount
of ROS formation with higher dose of light.
6. Quantication of PDT results by ow cytometry
The pathway through which cell death occurs depends on (1)
the photosensitizer and cell line combination, (2) the PDT
dosage and (3) the subcellular or subtissular localization of the
photosensitizer. Luo et al. showed that when photosensitizer
chloroaluminum phthalocyanine dispersed throughout the
cytoplasm 90% of murine leukemia P388 cells underwent
apoptosis at low light dosage.73 At higher dosage of light more
membrane photodamage was observed, which was found to
inhibit apoptosis. Jori et al. have shown that PDT with zinc
phthalocyanine (ZnPc) photosensitizer in MS-2 brosarcoma
induced random necrotic and apoptotic cell deaths due to
diﬀerent subcellular and/or subtissular distribution of the
photosensitizer.74 Here, PI and annexin V FITC staining was
completed aer PDT with 4 hours of post-PDT incubation to
evaluate cell death eﬃciency and pathways by ow cytometry.
Flow cytometry data are shown in Fig. 8. The annexin V FITC
uorescence intensity is plotted on the x-axis and the PI uorescence is plotted on the y-axis. The red dots correspond with
the control samples while the black dots correspond with
samples treated with PDT. The lower le quadrant in the dot
plots show cells which are viable. The lower right quadrants

This journal is © The Royal Society of Chemistry 2015

indicate cells which are positive for annexin V-FITC, but negative for PI indicating apoptotic cells. The upper le quadrants
show the fraction of the cell population exhibiting only PI
uorescence, indicating necrotic cells. The cell population in
the upper right quadrant is dual stained by annexin V-FITC and
PI. Looking at the ow cytometry data for PDT (black dots) in
OVCAR3 cell line (Fig. 8D), almost 75% of the cells are dual
stained, 14% cells are stained by PI only (necrotic) and 6% cells
are stained by annexin V-FITC (apoptotic).
For the dual stained cells (Fig. S6†), it is diﬃcult to distinguish the cell death pathway. Arguments can be made that the
cells have undergone either apoptotic death, or necrotic death,
or a random combination of necrotic and apoptotic death. The
rst possibility is that the cells have gone through apoptotic
death, which would give a positive signal for uorescence of
annexin V-FITC. Since these are in vitro experiments there is no
mechanism of phagocytosis to destroy the apoptotic cells,
which allows the cells go into the apoptotic necrosis stage. At
this stage the cells become permeable to PI stain and as a result
become dual stained. The second possibility is that the cells
have gone through necrosis, which would give a positive signal
for uorescence of PI. Aer cell death non-specic binding of
annexin V-FITC to the cells becomes possible so that the cells
get stained with annexin V-FITC as well and show up in the dual
stained quadrant of the ow cytometry data. The third possibility is that diﬀerent cells might have undergone both necrotic
or apoptotic deaths randomly to form a mixed population of
apoptotic and necrotic cells.
For clarity the ow cytometry data was also plotted as bar
graphs as shown in Fig. 8E–H. It can be seen from Fig. 8E that
the percentage of live cells in all the cell lines but OVCAR3 is
almost same as the control (no PDT) and that there is no death
because of PDT as these cell lines have not uptaken FNPs. On
the other hand, in OVCAR3 cell line the percent of live cells is
only 5. These data are very consistent with the data obtained by
MTS cell viability assay (Fig. 7). Thus ow cytometry and MTS
cell viability both conrm the eﬀect of PDT on the cell lines
studied here. The MIA PaCa-2 cell line was found to be very
sensitive to handle during culture and was the reason of
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Fig. 8 Flow cytometry to quantify cell mortality after PDT. Dot plots are for (A) TE 71, (B) MIA PaCa-2, (C) A549 and (D) OVCAR3 cell lines stained

with FITC annexin V and PI. The red dots are the cells from control and the black dots are the cells from PDT experiment. The four quadrants in
each plot are labeled for live (lower left), apoptotic (lower right), necrotic (upper left) and dual stained cells (upper right) along with percentages in
each quadrant. The data are plotted as bar graphs for clarity in E–H. (E) Percent cell viability in each cell line after PDT, (F) percent of necrotic cells
in each cell line after PDT, (G) percent of apoptotic cells after PDT, and (H) relation between % cell population with FNPs and % cell death after
PDT in each cell line. In each bar graph the percentages are compared with the corresponding control experiments.

showing approximately 85% live cells in both control and PDT
experiment. The OVCAR3 cell line has 14% necrotic cells
(Fig. 8F) while only 6.5% apoptotic cells (Fig. 8G). The percent of
dead cells is shown in Fig. 8H. OVCAR3 has almost 75% of dead
cells. The % cell death in OVCAR3 cell line can be directly
related to the % cell population which has uptaken FNPs (green
bars in Fig. 8H). The % cell population which has uptaken FNPs
is 84. When PDT is performed on these cells, the % cell death is
75 and can be directly related to the formation of ROS which
leads to death.

Conclusions
Blended MEH-PPV/PS-PEG-COOH nanoparticles conjugated
with folic acid (FNPs) were studied in vitro for use in PDT as next
generation photosensitizers with targeted delivery. The FNPs
were found to be selectively targeting cancer cell lines that
overexpress folate receptors (FR) and exhibited no dark toxicity.
In vitro PDT experiments show near complete cell mortality for
the cancer cell line that abundantly overexpresses the targeted
receptor (OVCAR3) while no cell mortality is observed for nontargeted (TE 71 normal control and MIA PaCa-2) or marginally
receptor overexpressing cell lines (A549). The high extinction

37954 | RSC Adv., 2015, 5, 37943–37956

coeﬃcient, eﬀective ROS generation, high degree of uptake
selectivity, absence of dark toxicity, inclusion of PEG which may
enhance circulation times for in vivo applications, and observation of cell mortality only for abundantly receptor overexpressing target cell line indicate the promising nature of this
photosensitizer system for targeted PDT.
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